SCHEMBL20988610

SCHEMBL20988610

CCOP(=O)(OCC)OC(=O)[C@]1(C)CC[C@]2(C)CC[C@]3(C)C4=CC=C5C(=CC(=O)C(O)=C5C)[C@]4(C)CC[C@@]3(C)[C@@H]2C1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A1 P22736 8/20 0.81
▸ TERT O14746 5/20 0.81
▸ PTPN1 P18031 1/20 0.75
▸ CASP1 P29466 1/20 0.75
▸ ABHD6 Q9BV23 1/20 0.75
▸ KDM4E B2RXH2 1/20 0.75
▸ TP53 P04637 1/20 0.75
▸ CYP3A4 P08684 1/20 0.75
▸ MAPT P10636 1/20 0.75
▸ HPGD P15428 1/20 0.75
▸ ALOX15 P16050 1/20 0.75
▸ ALOX12 P18054 1/20 0.75
▸ MAPK1 P28482 1/20 0.75
▸ SMN1; SMN2 Q16637 1/20 0.75
▸ TDP1 Q9NUW8 1/20 0.75
▸ HSP90AB1 P08238 5/20 0.74
▸ CASP3 P42574 5/20 0.74
▸ CDC37 Q16543 5/20 0.74
▸ HSP90AA1 P07900 1/20 0.72
▸ CCR6 P51684 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20988609 0.91 NR4A1 (0.81) NR4A1TERTPTPN1CASP1ABHD6
SCHEMBL12395123 0.89 NR4A1 (1.00) NR4A1TERTPTPN1CASP1ABHD6
SCHEMBL21527566 0.89 NR4A1 (0.79) NR4A1TERTPTPN1CASP1ABHD6
Pristimerin SCHEMBL17328930 0.86 NR4A1 (1.00) NR4A1TERTPTPN1CASP1ABHD6
Pristimerin SCHEMBL31238187 0.86 NR4A1 (1.00) NR4A1TERTPTPN1CASP1ABHD6
Pristimerin SCHEMBL30271494 0.86 NR4A1 (1.00) NR4A1TERTPTPN1CASP1ABHD6
Pristimerin SCHEMBL15020 0.86 NR4A1 (1.00) NR4A1TERTPTPN1CASP1ABHD6
SCHEMBL20988491 0.86 NR4A1 (0.89) NR4A1TERTPTPN1CASP1ABHD6
SCHEMBL18782084 0.85 NR4A1 (0.84) NR4A1TERTPTPN1CASP1ABHD6
Celastrol SCHEMBL17430781 0.84 HSP90AA1 (1.00) NR4A1TERTPTPN1CASP1ABHD6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10808005-B2 Ligand for orphan nuclear receptor Nur77 and uses thereof IXMEDICINE (XIAMEN) BIOLOGICAL TECHNOLOGY COMPANY LIMITED (CN) 2020-10-20 — — US disclosed
US-20190330261-A1 LIGAND FOR ORPHAN NUCLEAR RECEPTOR NUR77 AND USES THEREOF XIAMEN UNIVERSITY (CN) 2019-10-31 — — US disclosed
EP-3480207-A1 ORPHAN NUCLEAR RECEPTOR NUR77 LIGAND AND APPLICATION THEREOF Xiamen University (CN) 2019-05-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10808005-B2 Ligand for orphan nuclear receptor Nur77 and uses thereof NR2E3, NR0B1, NR0B2 NR4A1 15/4885TERT 2540/4885PTPN1 2999/4885
US-20190330261-A1 LIGAND FOR ORPHAN NUCLEAR RECEPTOR NUR77 AND USES THEREOF NR2E3, NR0B1, NR0B2 NR4A1 15/4885TERT 2540/4885PTPN1 2999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback